Managed Access Programs for SEG101, Crizanlizumab

Summary

The purpose of this registration is to list Managed Access Programs (MAPs) related to SEG101, Crizanlizumab

Timeline

Start

—

Primary completion

—

Completion

—

Publications

• DeBonnett L, Joshi V, Silva-Pinto AC, Colombatti R, Pasanisi A, Arcioni F, Cancado RD, Sarp S, Sarkar R, Soliman W. Real-World Evidence of Crizanlizumab Showing Reductions in Vaso-Occlusive Crises and Opioid Usage in Sickle Cell Disease. Eur J Haematol. 2025 Feb;114(2):293-302. doi: 10.1111/ejh.14323. Epub 2024 Oct 29.

Drugs

Indications